Showing 5071-5080 of 5957 results for "".
- WSJ: Troubled COVID-19 Data System Returning to CDChttps://modernod.com/news/wsj-troubled-covid-19-data-system-returning-to-cdc/2478184/The U.S. Department of Health and Human Services is reversing course on a change to the way hospitals report critical information on the coronavirus pandemic to the government, returning the responsibility for data collection to the Centers for Disease Control and Prevention, according to a W
- Alcon Kicks Off Global Social Media Campaignhttps://modernod.com/news/alcon-kicks-off-global-social-media-campaign/2478183/Alcon kicked off a global social media campaign, “Reasons to Love Lenses,” during Contact Lens Health Week taking place August 17–21. The new campaign raises consumer awareness of the benefits of contact lens wear. The campaign also reiterates the value of prescribing contact lenses for eye care
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- BVI Launches IPure Aspheric Monofocal IOL in the UShttps://modernod.com/news/bvi-launches-ipure-aspheric-monofocal-iol-in-the-us/2478172/BVI has entered the US IOL market with the launch of the IPure preloaded aspheric monofocal IOL. BVI says the IPure is the first and only preloaded aspheric monofocal IOL available in both a 1-piece and 3-piece design. IPure’s patented aspheric optic design provides high contract, hi
- EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccinehttps://modernod.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/The European Commission said that it concluded exploratory talks with Johnson & Johnson to buy Ad26.COV2.S, the company’s vaccine candidate against COVID-19. Under the potential deal, once a vaccine has shown to be safe and effective against the novel coronavirus, the Commission s
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- Gyroscope Therapeutics Initiates Phase 2 Program Evaluating its Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-initiates-phase-2-program-evaluating-its-investigational-gene-therapy-for-dry-amd/2478157/Gyroscope Therapeutics announced the initiation of its phase 2 program evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is a one-time AAV-based gene therapy that is delivered under the r
- Alcon Broadens US Availability of MARLO Digital Platformhttps://modernod.com/news/alcon-broadens-us-availability-of-marlo-digital-platform/2478153/Alcon announced broader US availability of its MARLO digital platform offered within independent OD practice. The platform allows patients to order, reorder and track their Alcon contact lens order online and have their lenses shipped right to their doorstep, while keeping the relationship and re